Big news from our parent company, Telix Pharmaceuticals!

The U.S. FDA has accepted the resubmitted New Drug Application for Pixclara® (TLX101-Px), Telix’s investigational PET imaging agent for recurrent and progressive glioma — bringing this brain cancer imaging tool one step closer to U.S. patients.

As part of the Telix family, RLS Radiopharmacies is proud to support the mission behind innovations like this — connecting radiopharmaceutical science to the patients and providers who need it most.

________________________
RLS RADIOPHARMACIES
Nationally Accredited.
Quality. Reliability. Flexibility.
www.rls.bio

#BrainCancerImaging
#TheRLSDifferece
#NuclearMedicine
#TelixPharmaceuticals

https://lnkd.in/evDCSERq